Kiora Pharmaceuticals (KPRX) Capital Expenditures (2016 - 2026)

Kiora Pharmaceuticals' (KPRX) quarterly Capital Expenditures came in at $5018.0 in Q1 2026, down 93.58% on a QoQ basis from $78163.0 in Q4 2025.

Kiora Pharmaceuticals (KPRX) Capital Expenditures (2016 - 2026) Analysis & Trends

Kiora Pharmaceuticals (KPRX) has 6 years of Capital Expenditures data on file, last reported at $5018.0 in Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to $5018.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115807.0 (up 357.17% YoY) and the FY2025 annual result came in at $110789.0, up 1670.92% from the prior year.
Capital Expenditures fell to $5018.0 in Q1 2026, from $78163.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $78163.0 in Q4 2025 to a low of -$45031.0 in Q4 2024.
A 3-year average of $14155.2 and a median of $5018.0 in 2026 frame the typical range for Capital Expenditures.
The widest YoY moves for Capital Expenditures: up 273.58% in 2025, down 273.58% in 2025.
Tracing KPRX's Capital Expenditures over 3 years: stood at -$45031.0 in 2024, then soared by 273.58% to $78163.0 in 2025, then sank by 93.58% to $5018.0 in 2026.
The last three Capital Expenditures figures came in at $5018.0 (Q1 2026), $78163.0 (Q4 2025), and $431.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.96 Bn	132.11 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	86.79 Bn	78.79 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	65.22 Bn	60.03 Bn	1.37 Bn	-
4	Moderna	60.20 Bn	55.06 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	42.19 Bn	37.09 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.43 Bn	28.12 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.65 Bn	10.26 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.16 Bn	26.32 Bn	-	251.02 Mn
10	Kiora Pharmaceuticals	15.94 Mn	15.94 Mn	-	23,456.00

Download Data